Tumorigenesis and Neoplastic Progression Overexpression of CXCL5 Is Associated With Poor Survival in Patients With Pancreatic Cancer

Epithelial neutrophil-activating peptide-78 (CXCL5), a member of the CXC chemokine family, has been shown to be involved in angiogenesis, tumor growth, and metastasis. The objective of this study was to determine the relationship between CXCL5 expression and tumor progression in human pancreatic cancer and to elucidate the mechanism underlying CXCL5-mediated tumor angiogenesis and cancer growth. We report herein that CXCL5 is overexpressed in human pancreatic cancer compared with paired normal pancreas tissue. Overexpression of CXCL5 is significantly correlated with poorer tumor differentiation, advanced clinical stage, and shorter patient survival. Patients with pancreatic cancer and CXCL5 overexpression who underwent resection of cancer had a mean survival time 25.5 months shorter than that of patients who did not overexpress CXCL5. Blockade of CXCL5 or its receptor CXCR2 by small-interfering RNA knockdown or antibody neutralization attenuated human pancreatic cancer growth in a nude mouse model. Finally, we demonstrated that CXCL5 mediates pancreatic cancer–derived angiogenesis through activation of several signaling pathways, including protein kinase B (Akt), extracellular signal–regulated kinase (ERK), and signal transducer and activator of transcription (STAT) in human endothelial cells. These data suggest that CXCL5 is an important mediator of tumor-derived angiogenesis and that it may serve as a

[1]  M. Raimondo,et al.  CXC‐chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer , 2009, International journal of cancer.

[2]  T. Gress,et al.  Pancreatic Intraepithelial Neoplasia Revisited and Updated , 2008, Pancreatology.

[3]  C. Rubie,et al.  Enhanced ENA-78 and IL-8 Expression in Patients with Malignant Pancreatic Diseases , 2008, Pancreatology.

[4]  Cornelis J H van de Velde,et al.  Disrupted Expression of CXCL5 in Colorectal Cancer Is Associated with Rapid Tumor Formation in Rats and Poor Prognosis in Patients , 2008, Clinical Cancer Research.

[5]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[6]  A. Sadanandam,et al.  Chemokines in tumor angiogenesis and metastasis , 2007, Cancer and Metastasis Reviews.

[7]  Kyung Hwa Park,et al.  CXCL5 overexpression is associated with late stage gastric cancer , 2007, Journal of Cancer Research and Clinical Oncology.

[8]  Michael J. Birrer,et al.  Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling , 2007, Oncogene.

[9]  D. Beer,et al.  Diversity of the angiogenic phenotype in non-small cell lung cancer. , 2007, American journal of respiratory cell and molecular biology.

[10]  H. Friess,et al.  Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. , 2006, Cancer letters.

[11]  W. A. Yeudall,et al.  Down-regulation of CXCL5 inhibits squamous carcinogenesis. , 2006, Cancer research.

[12]  J. Penn,et al.  Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events , 2006, Angiogenesis.

[13]  M. Burdick,et al.  CXC chemokines in angiogenesis , 2000, Journal of leukocyte biology.

[14]  N. Hay,et al.  Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo , 2005, Nature Medicine.

[15]  A. Dudley,et al.  A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. , 2005, The Biochemical journal.

[16]  Manish Gala,et al.  Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.

[17]  M. Lotze,et al.  Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. , 2005, Immunology letters.

[18]  D. Harrison,et al.  The JAK/STAT signaling pathway , 2004, Journal of Cell Science.

[19]  K. Sayama,et al.  Nuclear Translocation of Phosphorylated STAT3 Is Essential for Vascular Endothelial Growth Factor-induced Human Dermal Microvascular Endothelial Cell Migration and Tube Formation* , 2003, Journal of Biological Chemistry.

[20]  D. Stupack,et al.  Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli , 2003, Science.

[21]  K. Takaori,et al.  Clinicopathological features of pancreatic intraepithelial neoplasias and their relationship to intraductal papillary-mucinous tumors. , 2003, Journal of hepato-biliary-pancreatic surgery.

[22]  W. Murphy,et al.  The diverse role of chemokines in tumor progression: prospects for intervention (Review). , 2001, International journal of molecular medicine.

[23]  R H Hruban,et al.  Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions , 2001, The American journal of surgical pathology.

[24]  M. Burdick,et al.  The CXC Chemokine Receptor 2, CXCR2, Is the Putative Receptor for ELR+ CXC Chemokine-Induced Angiogenic Activity1 , 2000, The Journal of Immunology.

[25]  A. Richmond,et al.  Delayed wound healing in CXCR2 knockout mice. , 2000, The Journal of investigative dermatology.

[26]  P. Schwartzberg,et al.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. , 1999, Molecular cell.

[27]  S. Yonezawa,et al.  Immunohistochemical analysis of pericryptal fibroblast sheath and proliferating epithelial cells in human colorectal adenomas and carcinomas with adenoma components , 1999, Pathology international.

[28]  W. Gong,et al.  Chemokines and their role in tumor growth and metastasis. , 1998, Journal of immunological methods.

[29]  M. Iannettoni,et al.  Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. , 1998, The Journal of clinical investigation.

[30]  C. Bucana,et al.  Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. , 1998, Journal of the National Cancer Institute.

[31]  L. Mazzucchelli,et al.  The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. , 1997, Gastroenterology.

[32]  G. Zimmerman,et al.  Human endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion. , 1997, American journal of respiratory cell and molecular biology.

[33]  R. Strieter,et al.  Interferon‐α and interferon‐γ down‐regulate the production of interleukin‐8 and ENA‐78 in human monocytes , 1995, Journal of leukocyte biology.

[34]  M. Burdick,et al.  Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. , 1994, The Journal of clinical investigation.

[35]  R. Strieter,et al.  Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8 , 1991, The Journal of experimental medicine.

[36]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[37]  S. Kopetz,et al.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis , 2008, Cell and Tissue Research.

[38]  B. Dave,et al.  Autocrine Role of Interleukin-8 in Induction of Endothelial Cell Proliferation, Survival, Migration and MMP-2 Production and Angiogenesis , 2005, Angiogenesis.

[39]  C. Martínez-A,et al.  Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. , 2001, Annual review of immunology.

[40]  J. Folkman,et al.  Relation of vascular proliferation to tumor growth. , 1976, International review of experimental pathology.